3 Healthcare Stocks with Open Questions [Yahoo! Finance]
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: Yahoo! Finance
Players catalyzing medical advancements have benefited from elevated demand, and as a result, the industry has faired somewhat better than the broader market - over the past six months, healthcare stocks have recorded a loss of 1.1% versus a 2.8% decline for the S&P 500. Nevertheless, investors should tread carefully as the sector is heavily regulated, and businesses can be negatively impacted if the rules change. Keeping that in mind, here are three healthcare stocks that may face trouble. Myriad Genetics (MYGN) Market Cap: $429.2 million Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Why Are We Out on MYGN? Annual revenue growth of 4.6% over the last two years was below our standards for the healthcare sector Negative returns on capital sh
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer GlobeNewswire
- 2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off [Yahoo! Finance]Yahoo! Finance
- Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- 3 Reasons to Sell MYGN and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
MYGN
Earnings
- 2/23/26 - Beat
MYGN
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- MYGN's page on the SEC website